Transjugular liver biopsy

John H. Mcafee, Emmet B. Keeffe, Randall G. Lee, Josef Rosch

Research output: Contribution to journalArticle

124 Citations (Scopus)

Abstract

Although transjugular liver biopsy requires the availability of trained personnel, takes more time than percutaneous biopsy and is moderately expensive, it is a safe alternative technique for obtaining adequate liver tissue for diagnosis in special clinical situations. The usual indications for transjugular rather than percutaneous liver biopsy are (a) coagulation disorder (prothrombin time > 3 sec over control value and/or platelet count <60,000/cm3), (b) massive ascites and (c) desire to perform ancillary procedures, such as measurement of pressures or opacification of the hepatic veins and inferior vena cava. Less common indications for transjugular liver biopsy include failed percutaneous biopsy, massive obesity, small cirrhotic liver (increased risk and lower success rate) and suspected vascular tumor or peliosis hepatis. Results from several centers indicate that adequate or diagnostic liver tissue is obtained in 81% to 97% of cases. The typical length of the biopsy core ranges from 0.3 cm to 2.0 cm. Modification of the classic technique, particularly the adaptation of a Tru-Cut needle, shows promise in yielding longer cores of tissue with less fragmentation. Transjugular liver biopsy is performed with an acceptable complication rate that ranges 0% to 20%. The reported mortality of transjugular liver biopsy was 0 in three major centers and ranged from 0.1% to 0.5% in three other centers. Transjugular liver biopsy may be useful in obtaining diagnostic liver tissue not only in advanced chronic liver disease with coagulopathy, ascites or both, but also in patients with fulminant hepatic failure to better determine prognosis and the need for liver transplantation.

Original languageEnglish (US)
Pages (from-to)726-732
Number of pages7
JournalHepatology
Volume15
Issue number4
StatePublished - Apr 1992

Fingerprint

Biopsy
Liver
Ascites
Peliosis Hepatis
Hepatic Veins
Acute Liver Failure
Prothrombin Time
Inferior Vena Cava
Platelet Count
Liver Transplantation
Needles
Blood Vessels
Liver Diseases
Chronic Disease
Obesity
Pressure
Mortality
Neoplasms

ASJC Scopus subject areas

  • Hepatology

Cite this

Mcafee, J. H., Keeffe, E. B., Lee, R. G., & Rosch, J. (1992). Transjugular liver biopsy. Hepatology, 15(4), 726-732.

Transjugular liver biopsy. / Mcafee, John H.; Keeffe, Emmet B.; Lee, Randall G.; Rosch, Josef.

In: Hepatology, Vol. 15, No. 4, 04.1992, p. 726-732.

Research output: Contribution to journalArticle

Mcafee, JH, Keeffe, EB, Lee, RG & Rosch, J 1992, 'Transjugular liver biopsy', Hepatology, vol. 15, no. 4, pp. 726-732.
Mcafee JH, Keeffe EB, Lee RG, Rosch J. Transjugular liver biopsy. Hepatology. 1992 Apr;15(4):726-732.
Mcafee, John H. ; Keeffe, Emmet B. ; Lee, Randall G. ; Rosch, Josef. / Transjugular liver biopsy. In: Hepatology. 1992 ; Vol. 15, No. 4. pp. 726-732.
@article{cc1f1f4af5e641efa956b49c16b0a9d5,
title = "Transjugular liver biopsy",
abstract = "Although transjugular liver biopsy requires the availability of trained personnel, takes more time than percutaneous biopsy and is moderately expensive, it is a safe alternative technique for obtaining adequate liver tissue for diagnosis in special clinical situations. The usual indications for transjugular rather than percutaneous liver biopsy are (a) coagulation disorder (prothrombin time > 3 sec over control value and/or platelet count <60,000/cm3), (b) massive ascites and (c) desire to perform ancillary procedures, such as measurement of pressures or opacification of the hepatic veins and inferior vena cava. Less common indications for transjugular liver biopsy include failed percutaneous biopsy, massive obesity, small cirrhotic liver (increased risk and lower success rate) and suspected vascular tumor or peliosis hepatis. Results from several centers indicate that adequate or diagnostic liver tissue is obtained in 81{\%} to 97{\%} of cases. The typical length of the biopsy core ranges from 0.3 cm to 2.0 cm. Modification of the classic technique, particularly the adaptation of a Tru-Cut needle, shows promise in yielding longer cores of tissue with less fragmentation. Transjugular liver biopsy is performed with an acceptable complication rate that ranges 0{\%} to 20{\%}. The reported mortality of transjugular liver biopsy was 0 in three major centers and ranged from 0.1{\%} to 0.5{\%} in three other centers. Transjugular liver biopsy may be useful in obtaining diagnostic liver tissue not only in advanced chronic liver disease with coagulopathy, ascites or both, but also in patients with fulminant hepatic failure to better determine prognosis and the need for liver transplantation.",
author = "Mcafee, {John H.} and Keeffe, {Emmet B.} and Lee, {Randall G.} and Josef Rosch",
year = "1992",
month = "4",
language = "English (US)",
volume = "15",
pages = "726--732",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Transjugular liver biopsy

AU - Mcafee, John H.

AU - Keeffe, Emmet B.

AU - Lee, Randall G.

AU - Rosch, Josef

PY - 1992/4

Y1 - 1992/4

N2 - Although transjugular liver biopsy requires the availability of trained personnel, takes more time than percutaneous biopsy and is moderately expensive, it is a safe alternative technique for obtaining adequate liver tissue for diagnosis in special clinical situations. The usual indications for transjugular rather than percutaneous liver biopsy are (a) coagulation disorder (prothrombin time > 3 sec over control value and/or platelet count <60,000/cm3), (b) massive ascites and (c) desire to perform ancillary procedures, such as measurement of pressures or opacification of the hepatic veins and inferior vena cava. Less common indications for transjugular liver biopsy include failed percutaneous biopsy, massive obesity, small cirrhotic liver (increased risk and lower success rate) and suspected vascular tumor or peliosis hepatis. Results from several centers indicate that adequate or diagnostic liver tissue is obtained in 81% to 97% of cases. The typical length of the biopsy core ranges from 0.3 cm to 2.0 cm. Modification of the classic technique, particularly the adaptation of a Tru-Cut needle, shows promise in yielding longer cores of tissue with less fragmentation. Transjugular liver biopsy is performed with an acceptable complication rate that ranges 0% to 20%. The reported mortality of transjugular liver biopsy was 0 in three major centers and ranged from 0.1% to 0.5% in three other centers. Transjugular liver biopsy may be useful in obtaining diagnostic liver tissue not only in advanced chronic liver disease with coagulopathy, ascites or both, but also in patients with fulminant hepatic failure to better determine prognosis and the need for liver transplantation.

AB - Although transjugular liver biopsy requires the availability of trained personnel, takes more time than percutaneous biopsy and is moderately expensive, it is a safe alternative technique for obtaining adequate liver tissue for diagnosis in special clinical situations. The usual indications for transjugular rather than percutaneous liver biopsy are (a) coagulation disorder (prothrombin time > 3 sec over control value and/or platelet count <60,000/cm3), (b) massive ascites and (c) desire to perform ancillary procedures, such as measurement of pressures or opacification of the hepatic veins and inferior vena cava. Less common indications for transjugular liver biopsy include failed percutaneous biopsy, massive obesity, small cirrhotic liver (increased risk and lower success rate) and suspected vascular tumor or peliosis hepatis. Results from several centers indicate that adequate or diagnostic liver tissue is obtained in 81% to 97% of cases. The typical length of the biopsy core ranges from 0.3 cm to 2.0 cm. Modification of the classic technique, particularly the adaptation of a Tru-Cut needle, shows promise in yielding longer cores of tissue with less fragmentation. Transjugular liver biopsy is performed with an acceptable complication rate that ranges 0% to 20%. The reported mortality of transjugular liver biopsy was 0 in three major centers and ranged from 0.1% to 0.5% in three other centers. Transjugular liver biopsy may be useful in obtaining diagnostic liver tissue not only in advanced chronic liver disease with coagulopathy, ascites or both, but also in patients with fulminant hepatic failure to better determine prognosis and the need for liver transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0026596939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026596939&partnerID=8YFLogxK

M3 - Article

C2 - 1551649

AN - SCOPUS:0026596939

VL - 15

SP - 726

EP - 732

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 4

ER -